Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Patients who undergo bone marrow transplant for different types of cancer are exposed to many
treatments such as steroids and whole body radiation. These treatments make the transplant
possible but also make their bones weaker and more prone to fractures which can be a source
of significant disability and decreased quality of life for cancer survivors. Our trial will
investigate whether giving one dose of Zoledronic acid (a commonly used drug given to
preserve bone mass in osteoporosis) before bone marrow transplant can protect from the bone
loss caused by the transplant procedures. The investigators are also interested in studying
the complex interactions of bone, muscle and fat which are greatly affected after bone marrow
transplant.